SCHEMBL6840156

SCHEMBL6840156

CN(CCn1ccnc1)Cc1ccccc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.73
CYP3A4 P08684 2/20 0.73
CYP2D6 P10635 2/20 0.73
CYP2C9 P11712 1/20 0.73
ALOX15 P16050 1/20 0.73
CYP2C19 P33261 1/20 0.73
CYP19A1 P11511 2/20 0.54
CYP11B1 P15538 2/20 0.54
CYP11B2 P19099 2/20 0.54
TBXAS1 P24557 2/20 0.54
POLB P06746 1/20 0.54
MAPT P10636 1/20 0.54
QPCT Q16769 1/20 0.54
CYP4Z1 Q86W10 1/20 0.54
QPCTL Q9NXS2 1/20 0.54
MAOB P27338 1/20 0.49
LTA4H P09960 1/20 0.48
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
CARM1 Q86X55 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19766924 0.91 CYP1A2 (0.69) CYP1A2CYP3A4CYP2D6CYP2C9ALOX15
SCHEMBL14058750 0.84 CYP1A2 (1.00) CYP1A2CYP3A4CYP2D6CYP2C9ALOX15
SCHEMBL13889734 0.77 CYP19A1 (0.63) CYP1A2CYP3A4CYP2D6CYP2C9ALOX15
SCHEMBL14464746 0.76 CYP1A2 (0.50) CYP1A2CYP3A4CYP2D6CYP2C9ALOX15
SCHEMBL14465648 0.76 CYP19A1 (0.58) CYP1A2CYP3A4CYP2D6CYP2C9ALOX15
SCHEMBL14464756 0.76 CYP11B1 (0.58) CYP1A2CYP3A4CYP2D6CYP2C9ALOX15
SCHEMBL4720585 0.76 MAOB (0.49) CYP1A2CYP3A4CYP2D6CYP2C9ALOX15
SCHEMBL14465644 0.75 MEN1 (0.60) CYP1A2CYP3A4CYP2D6CYP2C9ALOX15
SCHEMBL409741 0.75 HMOX1 (0.72) CYP1A2CYP3A4CYP2D6CYP19A1CYP11B1
SCHEMBL14464749 0.74 ALDH1A1 (0.50) CYP1A2CYP3A4CYP2D6CYP2C9ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040087801-A1 Imidazolyl/benzimidazolyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension G.D. SEARLE & CO. 2004-05-06 US disclosed
US-20030130329-A1 Imidazolyl/benzimidazolyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension G.D. SEARLE & CO. 2003-07-10 US disclosed
US-20020115867-A1 Imidazolyl/benzimidazolyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension HANSON GUNNAR J (US) 2002-08-22 US disclosed
EP-0655059-B1 IMIDAZOLYL/BENZIMIDAZOLYL-TERMINATED ALKYLAMINO ETHYNYL ALANINE AMINO DIOL COMPOUNDS FOR TREATMENT OF HYPERTENSION SEARLE & CO (US) 1996-12-18 EP disclosed
US-5373017-A Renin inhibitor G. D. SEARLE & CO. (US) 1994-12-13 US disclosed
WO-1994004508-A1 IMIDAZOLYL/BENZIMIDAZOLYL-TERMINATED ALKYLAMINO ETHYNYL ALANINE AMINO DIOL COMPOUNDS FOR TREATMENT OF HYPERTENSION G.D. SEARLE & CO. (US) 1994-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087801-A1 Imidazolyl/benzimidazolyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension REN, AGTR1, AGTR2 CYP1A2 378/4885CYP3A4 245/4885CYP2D6 530/4885
US-20020115867-A1 Imidazolyl/benzimidazolyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension REN, AGT, AGTR1 CYP1A2 646/4885CYP3A4 174/4885CYP2D6 409/4885
US-20030130329-A1 Imidazolyl/benzimidazolyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension REN, AGTR1, AGTR2 CYP1A2 378/4885CYP3A4 245/4885CYP2D6 530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.